Home > Blog > Fda prior knowledge guidance a new framework for natural history evidence

2 min read

FDA Prior Knowledge Guidance: A New Framework for Natural History Evidence

June 22, 2026

What the FDA's prior knowledge guidance means for natural history evidence and shared datasets

On June 2, the FDA released a draft guidance, Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing. The guidance is not the first time the FDA has accepted natural history and real-world evidence. The 2019 rare disease natural history guidance and the more recent real-world data and evidence guidances already laid that groundwork, and external control arms are established practice.

What is new is that this document treats natural history and RWE as prior knowledge a sponsor can leverage across a program, and signals that the data can come from shared, multi-sponsor sources. For anyone working in rare disease, that is a meaningful shift in framing.

A few things are worth noting.

First, the evidence question moves upstream. The FDA is clear that natural history and RWE can support a program only when the data are fit for purpose, and it encourages that conversation early, through INTERACT and pre-IND meetings, before the IND is filed. In practice this means the design of the natural history evidence is now a development decision, not a downstream analysis choice. If you wait until you need an external control to ask whether your data can carry the weight, you have waited too long.

Second, the bar did not move. Leveraging prior knowledge is not a discount on rigor. The sponsor still has to justify why the data apply to this product, this population, and this context. A natural history dataset that was never built to support a comparison will not suddenly qualify because the guidance exists. The work of designing fit for purpose evidence is the same work it always was. The guidance just tells us the FDA is ready to receive it.

Third, and this is the part I find most interesting, the guidance accepts data from consortia and shared registries as valid prior knowledge, not only the data a sponsor holds internally. That principle is especially relevant to natural history work in rare disease. For many rare conditions, it is hard for a single sponsor to build a natural history cohort large enough to characterize the disease on its own, and a shared database can help close that gap. The guidance reads as an openness to pooling data, which is a notable shift in posture for the field.

If you are running a genome editing program in a rare disease, look now at whether your natural history and real-world evidence is designed to be leveraged, not just collected. Settle the fit for purpose question with the FDA before you file the IND, not after. And if a shared or consortium dataset already exists in your indication, carefully evaluate whether joining it is faster and more credible than building your own.

This is a document worth reading closely and weighing in on if you work in natural history or external control design.

What would make a shared natural history dataset credible enough for you to build a program on it?

LEARN MORE

 

 

 

2 min read

Connect with Veristat at Bio International Convention 2026

Jun 15, 2026  Veristat Events

June 22-25, 2026 – San Diego, CA

🌎 Bringing the Global Biopharma Community Together

We’re delighted to be attending...

2 min read

Connect with Veristat at DIA 2026

Jun 5, 2026  Veristat Events

June 14-18, 2026 – Philadelphia, PA

Veristat is excited to join industry leaders and innovators at the DIA 2026 Global...